HOUSE, PA — Third Arc Bio Inc. has administered the first dose of ARC101 to a patient in its inaugural first-in-human ...

Context Therapeutics Inc.’s CNTX share price has surged by 13.22%, which has investors questioning if this is right time to ...

ARC101 is the company's first bispecific antibody targeting Claudin 6 (CLDN6), optimized for best-in-class T cell engagement -- First-in-human study will evaluate the safety, tolerability, ...

PHILADELPHIA, March 6, 2025 /PRNewswire/ -- Integral Molecular, a leader in antibody discovery against membrane proteins, is pleased to announce that its out-licensed anti-Claudin 6 (CLDN6 ...

ARC101, a potential best-in-class T-cell engager that targets solid tumors expressing CLDN6, is being assessed in a ...

Context Therapeutics has dosed the first subject in the Phase I trial of CTIM-76, targeting claudin 6 (CLDN6)-positive gynaecologic and testicular cancers. The open-label trial aims to assess the ...

HC Wainwright reiterated their buy rating on shares of Context Therapeutics (NASDAQ:CNTX – Free Report) in a report released ...

CTIM-76 first patient dosed in January 2025Cash and cash equivalents of $94.4 million as of December 31, 2024Company expects its cash and cash ...

XmAb541 (CLDN6 x CD3), a first-in-class, tumor-targeted, T-cell engaging 2+1 bispecific antibody in development for patients with advanced solid tumors expressing CLDN6. Like XmAb819, XmAb541 ...

ARC101 is the company's first bispecific antibody targeting Claudin 6 (CLDN6), optimized for best-in-class T cell engagement -- First-in-human study will evaluate the safety, tolerability ...